Cargando…

A predictive model involving serum uric acid, C-reactive protein, diabetes, hypercholesteremia, multiple lesions for restenosis risk in everolimus-eluting stent-treated coronary heart disease patients

PURPOSE: As a second-generation drug-eluting stent, the restenosis risk factors of the everolimus-eluting stent (EES) lack sufficient evidence. Therefore, the study investigated the in-stent restenosis occurrence and its predictive factors among patients with coronary heart disease (CHD) who underwe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Qiang, Zhao, Ying, Wang, Haiyan, Zhao, Jiayu, Wang, Xun, Shi, Jianping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403046/ https://www.ncbi.nlm.nih.gov/pubmed/36035940 http://dx.doi.org/10.3389/fcvm.2022.857922

Ejemplares similares

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model
por: Lim, Kyung Seob, et al.
Publicado: (2013)

Serum glycated albumin is associated with in-stent restenosis in patients with acute coronary syndrome after percutaneous coronary intervention with drug-eluting stents: An observational study
por: Lin, Xiao Long, et al.
Publicado: (2022)

Risk investigation of in-stent restenosis after initial implantation of intracoronary drug-eluting stent in patients with coronary heart disease
por: Xi, Hongfei, et al.
Publicado: (2023)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Relationship between uric acid to albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting
por: Liu, Wenquan, et al.
Publicado: (2023)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Drug- and Gene-eluting Stents for Preventing Coronary Restenosis
por: Lekshmi, Kamali Manickavasagam, et al.
Publicado: (2017)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

Impact of the Distance from the Stent Edge to the Residual Plaque on Edge Restenosis following Everolimus-Eluting Stent Implantation
por: Takahashi, Masao, et al.
Publicado: (2015)

Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions
por: Kassaian, SE, et al.
Publicado: (2010)

In-stent restenosis due to delayed healing of abluminal bioresorbable polymer everolimus-eluting stent: insight from histopathological evaluation with directional coronary atherectomy
por: Yamamoto, Hiroyuki, et al.
Publicado: (2021)

Preclinical Evaluation of a Novel Polymer-free Everolimus-eluting Stent in a Mid-term Porcine Coronary Restenosis Model
por: Cho, Kyung Hoon, et al.
Publicado: (2021)

Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold
por: Madanchi, Mehdi, et al.
Publicado: (2021)

Comparison of Drug-Coated Balloon Angioplasty vs. Drug-Eluting Stent Implantation for Drug-Eluting Stent Restenosis in the Routine Clinical Practice: A Meta-Analysis of Randomized Controlled Trials
por: Zhu, Yong, et al.
Publicado: (2021)

FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI
por: Song, Tingting, et al.
Publicado: (2021)

Drug-Coated Balloons versus Everolimus-Eluting Stents in Patients with In-Stent Restenosis: A Pair-Wise Meta-Analysis of Randomized Trials
por: Peng, Nina, et al.
Publicado: (2020)

Clinical results of everolimus-eluting stents and sirolimus-eluting stents in patients undergoing percutaneous coronary intervention
por: Jafaripour, Iraj, et al.
Publicado: (2023)

Heavy Coronary Calcium Mimicking In-Stent Restenosis
por: Park, Jeong-Hwan, et al.
Publicado: (2011)

Conformability in everolimus-eluting bioresorbable scaffolds compared with metal platform coronary stents in long lesions
por: Fam, Jiang Ming, et al.
Publicado: (2017)

Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial
por: Arroyo, Diego, et al.
Publicado: (2014)

Everolimus-eluting stents in interventional cardiology
por: Townsend, Jacob C, et al.
Publicado: (2012)

Intracoronary brachytherapy for in-stent restenosis of drug-eluting stents
por: Ohri, Nisha, et al.
Publicado: (2015)

Prevalence, predictors, and management for balloon uncrossable or undilatable lesions in patients undergoing percutaneous coronary intervention with in-stent restenosis chronic total occlusion
por: Wang, Yong, et al.
Publicado: (2023)

Nanoparticle Drug- and Gene-eluting Stents for the Prevention and Treatment of Coronary Restenosis
por: Yin, Rui-Xing, et al.
Publicado: (2014)

Intravascular imaging in coronary stent restenosis: Prevention, characterization, and management
por: Abouelnour, Amr, et al.
Publicado: (2022)

Comparison of new-generation drug-eluting stents versus drug-coated balloon for in-stent restenosis: a meta-analysis of randomised controlled trials
por: Cai, Jin-Zan, et al.
Publicado: (2018)

Drug-eluting stent in-stent restenosis and re-restenosis: A hard time story
por: Dinesch, Violeta, et al.
Publicado: (2017)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V(®))
por: Sheiban, Imad, et al.
Publicado: (2008)

Case series of coronary artery aneurysms after Everolimus eluting stent implantation and comparison with Sirolimus eluting stents
por: Sharma, Raghav, et al.
Publicado: (2022)

Stent Fracture after Everolimus-Eluting Stent Implantation
por: Almasood, Ali S., et al.
Publicado: (2011)

Early definite stent thrombosis with everolimus-eluting stents
por: Naito, Ryo, et al.
Publicado: (2015)

Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent
por: Dalos, Daniel, et al.
Publicado: (2016)

New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent
por: Wang, Jian-Long, et al.
Publicado: (2018)

Investigation Into the Risk Factors Related to In-stent Restenosis in Elderly Patients With Coronary Heart Disease and Type 2 Diabetes Within 2 Years After the First Drug-Eluting Stent Implantation
por: Yi, Ming, et al.
Publicado: (2022)

One-Year Outcome of Everolimus-Eluting Stents Versus Biolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention
por: Alidoosti, Mohammad, et al.
Publicado: (2016)

Clinical outcomes in patients treated for coronary in-stent restenosis with drug-eluting balloons: Impact of high platelet reactivity
por: Tornyos, Adrienn, et al.
Publicado: (2017)

Therapeutic Strategy for In-Stent Restenosis Based on the Restenosis Pattern After Drug-Eluting Stent Implantation
por: Kim, Ki-Hun, et al.
Publicado: (2009)

Response to drug-eluting stent in-stent restenosis and re-restenosis: A hard time story
Publicado: (2017)

Everolimus-eluting stents versus sirolimus-eluting stents in patients with cardiac allograft vasculopathy
por: Hawranek, Michał, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bpmj4i2n8j1i1u52jukrakh864